US protection ending in 2037: Heart and blood vessels
As of the edition of 20 October 2026, 8 drugs have US protection that ends in 2037 in heart and blood vessels; 5 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
8 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Depemokimab | Ends 2037 (computed from the first US licence) | Marketed | GSK | IL5 | 0 |
| Entrectinib | Ends 2037 (patent) | Marketed | Roche | ALK, NTRK1, NTRK2 | 4 |
| Lerodalcibep | Ends 2037 (computed from the first US licence) | Marketed | LIB Therapeutics | PCSK9 | 1 |
| Linvoseltamab | Ends 2037 (computed from the first US licence) | Marketed | Regeneron | CD3D, CD3E, CD3G | 1 |
| Orforglipron | Ends 2037 (patent) | Marketed | Eli Lilly | GLP1R | 0 |
| Sebetralstat | Ends 2037 (patent) | Marketed | Chiesi Farmaceutici | KLKB1 | 1 |
| Zanubrutinib | Ends 2037 (patent) | Marketed | BeiGene | BTK | 1 |
| Zuranolone | Ends 2037 (patent) | Marketed | Biogen | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2037 in heart and blood vessels
In the product5 of these 8 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.